San Francisco, CA (UroToday.com) — An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of prostate cancers which have become ‘addicted’ to growth signals, a major phase III clinical trial has shown.
San Francisco, CA (UroToday.com) — An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of prostate cancers which have become ‘addicted’ to growth signals, a major phase III clinical trial has shown.